Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...
And although it's a signal that branded versions of tirzepatide-based drugs – Mounjaro, for diabetes, and Zepbound, approved at the end of 2023 for weight loss – are more widely available ...